TherOx has appointed Keith Grossman to its board of directors.
“Keith is a recognised leader in our industry, and brings a wealth of experience and judgment in guiding innovative device companies through aggressive growth, strategic change, and value creation,” says Kevin T Larkin, president and chief executive officer of TherOx.
SuperSaturated oxygen (SSO2) therapy is intended to provide interventional cardiologists with the first treatment option beyond percutaneous coronary intervention (PCI) to salvage heart muscle in heart attack patients and thus reduce infarct size.
Grossman has over 30 years of experience in the medical device field. Grossman served most recently, and for the second time, as the president, chief executive officer and director of Thoratec Corporation, leading up to its 2015 sale to St Jude Medical. Prior to Thoratec, he served as president, chief executive officer and director of Conceptus, a women’s health medical device company, leading up to its sale to Bayer Healthcare. Prior to Conceptus, Grossman served as managing director of TPG (Texas Pacific Group), a private equity firm, as a member of its healthcare investment team. Before TPG, Grossman served as Thoratec’s president, chief executive officer and director for the first ten years of its growth as a commercial company. Mr. Grossman currently serves as a member of the board of directors of ZELTIQ Aesthetics, and as chairman of Outset Medical, and previously served as a member of the board of directors of Intuitive Surgical, Kyphon, and a number of privately held medical device companies. Grossman received a B.S. in life sciences from The Ohio State University and an MBA from Pepperdine University.
